Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099934 | 0.90 | DRD4 (0.50) | KDM4EALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL13059256 | 0.81 | NPC1 (0.58) | ALDH1A1MAPTMAPK1NPSR1DRD4 | |
| SCHEMBL13461862 | 0.81 | DRD2 (0.52) | ALDH1A1LMNAMAPTDRD4DRD2 | |
| SCHEMBL9668483 | 0.80 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTDRD4DRD2 | |
| SCHEMBL6557649 | 0.79 | MAOB (0.57) | KDM4EALDH1A1LMNAMAPK1DRD4 | |
| SCHEMBL6343489 | 0.79 | NPC1 (0.37) | LMNAMAPTMAPK1NPSR1L3MBTL1 | |
| SCHEMBL11285757 | 0.78 | KCNA3 (0.58) | ALDH1A1LMNADRD4DRD2DRD3 | |
| SCHEMBL7934084 | 0.78 | NPC1 (0.39) | ALDH1A1LMNAMAPTMAPK1NPSR1 | |
| SCHEMBL10358299 | 0.77 | RAB9A (0.62) | KDM4EALDH1A1LMNAMAPTMAOB | |
| SCHEMBL18235025 | 0.77 | DRD4 (0.57) | KDM4EALDH1A1MAPK1DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-08-01 | — | — | US | disclosed |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-05-16 | — | — | US | disclosed |
| US-9580437-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| WO-2016103155-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| EP-1140896-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6235771-B1 | AIDS THERPAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| WO-2000037455-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
| US-5919793-A | QUINUCLIDINE DERIVATIVES, SQUALENE SYNTHETASE INHIBITORS, ANTICHOLESTEROL AGENTS | ZENECA LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| WO-1994025459-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | KDM4E 146/4885ALDH1A1 529/4885LMNA 4539/4885 |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | KDM4E 146/4885ALDH1A1 529/4885LMNA 4539/4885 |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, BMI1 | KDM4E 70/4885ALDH1A1 344/4885LMNA 4234/4885 |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KDM4E 146/4885ALDH1A1 529/4885LMNA 4539/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | KDM4E 70/4885ALDH1A1 344/4885LMNA 4234/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KDM4E 146/4885ALDH1A1 529/4885LMNA 4539/4885 |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KDM4E 146/4885ALDH1A1 529/4885LMNA 4539/4885 |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KDM4E 146/4885ALDH1A1 529/4885LMNA 4539/4885 |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KDM4E 146/4885ALDH1A1 529/4885LMNA 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.